Specialties
Reports that name this provider
- Ibogaine Treatment Legality in United Kingdom
- Conducted DemeRx's Phase 1/2a ibogaine study (DMX-1002) for opioid use disorder, with first subjects dosed in September 2021. Described in the report as one of Europe's largest clinical development organisations.